Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kainos delivers in-line results, cautious outlook

(Sharecast News) - IT services group Kainos met expectations with its full-year results on Monday, with profits falling by a quarter amid tough trading conditions, as the company delivered a cautious outlook. "While the long-term drivers in our market remain strong, and our near-term performance is supported by a healthy pipeline, a significant contracted backlog, and a strong balance sheet, we believe it is prudent to maintain our cautious stance given continued volatility in the global macroeconomic environment," Kainos said.

Revenues totalled £367.2m in the year ended 31 March, down 4% year-on-year, as strong growth in Workday Products revenue was balanced with customer delays in Digital Services and softer market conditions and increased competition in Workday Services.

Kainos, which in March announced it would cut its global workforce by 7% to "create capacity for investment", reported a statutory pre-tax profit of £48.6m, down 25% on the year before, while adjusted pre-tax profit fell 15% to £65.6m.

Nevertheless, the firm reported a year-end contracted backlog of £368.2m, up 3% over the year before.

Despite the uncertain outlook, the company announced that it would conduct an additional £30m share buyback over the next six months, following the £30m buyback completed in earlier this month.

Kainos shares were down around 4% at 782.5p by 0818 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.